Source: TaiMed Biologics
There are no serious adverse events in this study. The drug-related adverse events are mild to moderate. There are no notable safety signals on clinical laboratory parameters.
There are no differences in HIV-1 viral load due to the change from IV Infusion to IV Push.
No participants have an increase in plasma viral load to levels above 1,000 copies/mL on 2 consecutive measurements at least 2 weeks apart.
No anti-Trogarzo® antibodies detected. No immunogenicity concerns of Trogarzo®